Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm labor.
Serradeil-Le Gal C, Valette G, Foulon L, Germain G, Advenier C, Naline E, Bardou M, Martinolle JP, Pouzet B, Raufaste D, Garcia C, Double-Cazanave E, Pauly M, Pascal M, Barbier A, Scatton B, Maffrand JP, Le Fur G. Serradeil-Le Gal C, et al. Among authors: maffrand jp. J Pharmacol Exp Ther. 2004 Apr;309(1):414-24. doi: 10.1124/jpet.103.061200. Epub 2004 Jan 13. J Pharmacol Exp Ther. 2004. PMID: 14722330
Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.
Serradeil-Le Gal C, Wagnon J, Simiand J, Griebel G, Lacour C, Guillon G, Barberis C, Brossard G, Soubrié P, Nisato D, Pascal M, Pruss R, Scatton B, Maffrand JP, Le Fur G. Serradeil-Le Gal C, et al. Among authors: maffrand jp. J Pharmacol Exp Ther. 2002 Mar;300(3):1122-30. doi: 10.1124/jpet.300.3.1122. J Pharmacol Exp Ther. 2002. PMID: 11861823
4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization.
Gully D, Geslin M, Serva L, Fontaine E, Roger P, Lair C, Darre V, Marcy C, Rouby PE, Simiand J, Guitard J, Gout G, Steinberg R, Rodier D, Griebel G, Soubrie P, Pascal M, Pruss R, Scatton B, Maffrand JP, Le Fur G. Gully D, et al. Among authors: maffrand jp. J Pharmacol Exp Ther. 2002 Apr;301(1):322-32. doi: 10.1124/jpet.301.1.322. J Pharmacol Exp Ther. 2002. PMID: 11907190
SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.
Emonds-Alt X, Proietto V, Steinberg R, Oury-Donat F, Vigé X, Vilain P, Naline E, Daoui S, Advenier C, Le Fur G, Maffrand JP, Soubrié P, Pascal M. Emonds-Alt X, et al. Among authors: maffrand jp. J Pharmacol Exp Ther. 2002 Dec;303(3):1171-9. doi: 10.1124/jpet.102.040162. J Pharmacol Exp Ther. 2002. PMID: 12438541
4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders.
Griebel G, Simiand J, Steinberg R, Jung M, Gully D, Roger P, Geslin M, Scatton B, Maffrand JP, Soubrié P. Griebel G, et al. Among authors: maffrand jp. J Pharmacol Exp Ther. 2002 Apr;301(1):333-45. doi: 10.1124/jpet.301.1.333. J Pharmacol Exp Ther. 2002. PMID: 11907191
Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.
Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P. Griebel G, et al. Among authors: maffrand jp. Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6370-5. doi: 10.1073/pnas.092012099. Epub 2002 Apr 16. Proc Natl Acad Sci U S A. 2002. PMID: 11959912 Free PMC article.
Structure and stereochemistry of the active metabolite of clopidogrel.
Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P, Pascal M, Herbert JM, Maffrand JP, Picard C. Pereillo JM, et al. Among authors: maffrand jp. Drug Metab Dispos. 2002 Nov;30(11):1288-95. doi: 10.1124/dmd.30.11.1288. Drug Metab Dispos. 2002. PMID: 12386137
Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats.
Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C, Chabbert M, Cruccioli N, Pfersdorff C, Roque C, Arnone M, Croci T, Soubrié P, Oury-Donat F, Maffrand JP, Scatton B, Lacheretz F, Le Fur G, Herbert JM, Bensaid M. Gary-Bobo M, et al. Among authors: maffrand jp. Hepatology. 2007 Jul;46(1):122-9. doi: 10.1002/hep.21641. Hepatology. 2007. PMID: 17526015
133 results